New trends in specific immunoadsorption

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22

Stoffel, 1981, Application of specific extrracorporeal removal of low density lipoprotein in familial hypercholesterolaemia, Lancet, 1005, 10.1016/S0140-6736(81)91213-7

Thompson, 1957, Plasma exchange in the management of homozygous familial hypercholesterolaemia, Lancet, 1208

Borberg, 1988, Treatment of familial hypercholesterolemia by means of specific immunoadsorption, J. Clin. Apher., 4, 59, 10.1002/jca.2920040204

Borberg, 1990, The current status of low-density lipoprotein apheresis, Curr. Stud. Hematol. Blood Transf., 57, 239, 10.1159/000418563

Bosch, 2002, Direct adsorption of lipoproteins study group. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first long-term multicenter study using DALI apheresis, J. Clin. Apher., 17, 161, 10.1002/jca.10035

Utermann, 1989, The mysteries of lipoprotein(a), Science, 246, 904, 10.1126/science.2530631

Seed, 1990, Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia, N. Engl. J. Med., 322, 1494, 10.1056/NEJM199005243222104

Pokrowski, 1991, Immunosorbent for selective removal of lipoprotein(a) from human plasma: in vitro study, Artif. Org., 15, 136, 10.1111/j.1525-1594.1991.tb00771.x

Ullrich, 1996, Lipoprotein(a)-apheresis in the secondary prevention of coronary heart disease, Transfus. Sci., 17, 511, 10.1016/S0955-3886(96)00049-5

Ullrich, 1998, Lipoprotein(a)-apheresis in severe coronary heart disease: an immunoadsorption method, Artif. Organs., 22, 135, 10.1046/j.1525-1594.1998.05080.x

Oette, 1988, Variables involved in regression of atherosclerosis in familial hypercholesterolemic patients under long-term LDL-apheresis, Plasma Ther. Transfus. Technol., 9, 17, 10.1016/0278-6222(88)90026-5

Haas, 2002, Long-term treatment of myasthenia gravis with immunoadsorption, J. Clin. Apher., 17, 84, 10.1002/jca.10023

Takamori, 2001, Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor, Ther. Apher., 5, 340, 10.1046/j.1526-0968.2001.00367.x

Haupt, 2000, Ther. Apher., 43, 195, 10.1046/j.1526-0968.2000.00183.x

Ullrich, 1998, Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment, Transf. Sci., 19, 33, 10.1016/S0955-3886(97)00100-8

Mansouri-Taleghani, 1998, Therapy of coagulation factor VIII autoantibodies with long term extracorporeal protein A adsorption and immunosuppression, Transf. Sci., 19, 39, 10.1016/S0955-3886(97)00101-X

Nilsson, 1993, Treatment of patients with factor VIII and IX inhibitors, Thromb. Haemost., 70, 56, 10.1055/s-0038-1646159

Fürst, 2000, Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomised trial. Prosorba trial investigators, Ther. Apher., 4, 363, 10.1046/j.1526-0968.2000.004005363.x

Gaubitz, 2003, Immunoadsorption in systemic lupus erythematosus: different techniques and their current role in medical therapy, Ther. Apher. Dial., 7, 183, 10.1046/j.1526-0968.2003.00040.x

Hiepe, 1999, C1q: a multifunctional ligand for a new immunoadsorption treatment, Ther. Apher., 3, 246, 10.1111/j.1091-6660.1999.t01-2-.x

Pfüller, 2001, Successful treatment of patients with systemic lupus erythematosus with a C1q column: a pilot study, Arthr. Rheum., 44, 1962, 10.1002/1529-0131(200108)44:8<1962::AID-ART335>3.0.CO;2-R

Gaskin, 2001, Plasmapheresis in antineutrophil cytoplasmic antibody associated systemic vasculitis, Ther. Apher., 5, 176, 10.1046/j.1526-0968.2001.00300.x

Elliott, 1998, Semi-specific immuno-adsorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases, Autoimmunity, 28, 163, 10.3109/08916939808996285

Schmidt, 2003, Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus, Brit. J. Dermatol., 148, 1222, 10.1046/j.1365-2133.2003.05302.x

Lüftl, 2003, Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber, Brit. J. Dermatol., 149, 598, 10.1046/j.1365-2133.2003.05513.x

Staudt, 2001, Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution, Circulation, 103, 2681, 10.1161/01.CIR.103.22.2681

Müller, 2000, Immunoglobulin adsorption in patients with dilated cardiomyopathy, Circulation, 101, 385, 10.1161/01.CIR.101.4.385

Mobini, 2003, Hemodynamic improvement and removal of autoantibodies against ß1-adrenegic receptor by immunoadsorption therapy in dilated cardiomyopathy, J. Autoimmun., 20, 345, 10.1016/S0896-8411(03)00042-8

Ronspeck, 2003, Peptide based adsorbers for therapeutic immunoadsorption, Ther. Apher. Dial, 7, 91, 10.1046/j.1526-0968.2003.00017.x

Rabitsch, 2003, Removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation, Nephrol. Dial. Transplant, 18, 2405, 10.1093/ndt/gfg364

Rabitsch, 2003, Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with IgG-Therasorb immunoadsorption, Bone Marrow Transpl., 32, 1015, 10.1038/sj.bmt.1704264

Tyden, 2003, Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab, Transplantation, 76, 730, 10.1097/01.TP.0000078622.43689.D4

Tanabe, 1998, Long-term results of ABO-incompatible living kidney transplantation, Transplantation, 65, 256

Guthrie, 1989, Immune thrombocytopenia purpura: a pilot study of staphylococcal protein A immunomodulation in refractory patients, Semin. Hematol., 26, 3

Snyder, 1992, Experience with protein A-immunoadsorption in treatment resistant adult immune thrombocytopenic purpura, Blood, 79, 2237, 10.1182/blood.V79.9.2237.2237

Fabris, 2000, Treatment of refractory ITP with extracorporeal immunoadsorption over a protein A sepharose column: a report of two cases, Haematologica, 8

Bosch, 2001, Extracorporeal plasma treatment in primary and recurrent focal segmental glomerular sclerosis: a review, Ther. Apher., 5, 155, 10.1046/j.1526-0968.2001.00318.x

Ponticelli, 2003, Other immunosuppressive agents for focal segmental glomerulosclerosis, Sem. Nephrol., 23, 242, 10.1053/snep.2003.50023

Waxenberger, 1992, Rheologic studies before and after therapeutic cytapheresis and plasma exchange, Beitr. Infusionsther., 30, 301

Borberg, 2001, The current status of extracorporeal haemorheotherapy: from haemodilution via cascade filtration to rheohaemapheresis, Transf. Apher. Sci., 24, 57, 10.1016/S0955-3886(00)00126-0

Brunner, 1995, Change in hemorheological and biochemical parameters following membrane differential filtration, Int. J. Artif Organs., 18, 794, 10.1177/039139889501801208

Brunner, 2000, Retina, 20, 483

Richter, 2001, Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience, Ther. Apher., 5, 335, 10.1046/j.1526-0968.2001.00335.x

Suckfüll, 2002, Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial, Lancet, 360, 1811, 10.1016/S0140-6736(02)11768-5

Ullrich H, Kleinjung T, Steffens T, Jacob P, Schmitz G, Strutz J. Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. In print